Get the Stockscreener App
2.32
0.00%
0.00
Relmada Therapeutics Inc stock is traded at $2.32, with a volume of 50,273.
It is up +0.00% in the last 24 hours and up +15.42% over the past month.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
See More
Previous Close:
$2.32
Open:
$2.31
24h Volume:
50,273
Relative Volume:
0.07
Market Cap:
$74.02M
Revenue:
-
Net Income/Loss:
$-98.79M
P/E Ratio:
-0.7095
EPS:
-3.27
Net Cash Flow:
$-51.66M
1W Performance:
+10.48%
1M Performance:
+15.42%
6M Performance:
+619.60%
1Y Performance:
-33.33%
1-Day Range:
$2.19
$2.37
1-Week Range:
$2.19
$2.63
52-Week Range:
$0.2404
$3.6723
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
3.32 | 3.71B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.07 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.39 | 174.62M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2657 | 587.26M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.31 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-05-24 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
Will Relmada Therapeutics Inc. stock recover faster than marketJuly 2025 Intraday Action & Daily Oversold Bounce Ideas - newser.com
Relmada Therapeutics (RLMD) to Release Earnings on Thursday - MarketBeat
Will breakout in Relmada Therapeutics Inc. lead to full recoveryJuly 2025 Momentum & Community Supported Trade Ideas - newser.com
What to expect from Relmada Therapeutics Inc. in the next 30 daysInsider Buying & Free Technical Pattern Based Buy Signals - newser.com
Why Relmada Therapeutics Inc. stock attracts global investorsMarket Volume Report & Free High Accuracy Swing Entry Alerts - newser.com
Is Relmada Therapeutics Inc. showing signs of accumulation2025 Support & Resistance & Safe Swing Trade Setups - newser.com
Smart tools for monitoring Relmada Therapeutics Inc.’s price actionJobs Report & AI Forecast Swing Trade Picks - newser.com
Will Relmada Therapeutics Inc. (4E2) stock beat revenue estimatesChart Signals & Free Fast Gain Swing Trade Alerts - newser.com
Why Relmada Therapeutics Inc. stock is a value investor pickJuly 2025 EndofMonth & Fast Exit and Entry Strategy Plans - newser.com
Will Relmada Therapeutics Inc. stock gain from lower inflation2025 Trading Recap & Scalable Portfolio Growth Methods - newser.com
Why Relmada Therapeutics Inc. stock remains a top recommendationMarket Growth Summary & Short-Term Trading Opportunity Alerts - newser.com
Is Relmada Therapeutics Inc. building a consolidation baseChart Signals & Community Trade Idea Sharing Platform - newser.com
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relmada Therapeutics Inc Stock (RLMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
| Kelly Paul Edward | Chief Operating Officer |
May 16 '25 |
Buy |
0.43 |
200,000 |
86,060 |
412,295 |
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
| Shenouda Maged | Chief Financial Officer |
May 20 '25 |
Buy |
0.52 |
60,000 |
31,422 |
288,335 |
| Shenouda Maged | Chief Financial Officer |
May 16 '25 |
Buy |
0.44 |
50,000 |
22,100 |
138,335 |
| Ence Chuck | CA and CO |
May 16 '25 |
Buy |
0.45 |
228,961 |
103,330 |
267,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 20 '25 |
Buy |
0.56 |
147,686 |
82,246 |
734,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 16 '25 |
Buy |
0.45 |
172,314 |
77,472 |
556,338 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 19 '25 |
Buy |
0.50 |
30,000 |
14,994 |
586,338 |
1.68%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):